StemCells, Inc. and Microbot Medical to Combine in Cross-Border Deal to Develop Robotics-Based Medical Devices
Ropes & Gray advised StemCells, Inc. in its definitive merger agreement with Israel-based Microbot Medical Ltd., announced Aug. 15, 2016. The combined company will pursue the development of robotics-based medical devices for the treatment of cerebrospinal fluid and gastrointestinal disorders, as well as other conditions. Completion of the merger is subject to approval by StemCells and Microbot shareholders and certain regulatory approvals and customary conditions.
The Ropes & Gray team was led by securities & public companies partner Marko Zatylny and included business restructuring partner James Wilton and tax partner Pamela Glazier.